Mohs Micrographic Surgery Utilization in the Medicare Population, 2009

被引:19
作者
Donaldson, Matthew R. [1 ,2 ]
Coldiron, Brett M. [3 ,4 ]
机构
[1] Mt W Dermatol, Grand Junction, CO USA
[2] TriHlth Good Samaritan, Cincinnati, OH USA
[3] Skin Canc Ctr, Cincinnati, OH USA
[4] Univ Cincinnati, Dept Dermatol, Cincinnati, OH USA
关键词
NONMELANOMA SKIN-CANCER; UNITED-STATES; FELLOWSHIP; EXPERIENCE; AUSTRALIA;
D O I
10.1111/j.1524-4725.2012.02464.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Mohs micrographic surgery (MMS) is the criterion standard treatment for high-risk skin cancers. Few data on current MMS Utilization are available. Objective To better understand current trends in MMS use in the Medicare population. Methods and Materials The 2009 Medicare Limited Data Set Standard Analytic File (LDSSAF), carrier claims, 5% sample and the Physician Supplier Procedure Master File (PSPMF) 100% summary were analyzed. Results In 2009, 558,447 Medicare MMS cases were performed, with an average of 1.75 stages per case. In the 5% claims sample, 0.3% and 1.3% of MMS cases were performed for melanoma and carcinoma in situ, respectively. Total annual volume predictions for 1,777 providers showed a left-shifted curve. 65.8% of LDSSAF cases had same-day MMS repairs: 48.7% of repairs were complex, 9.8% intermediate, 32.4% flaps, and 7.4% full-thickness skin grafts. Conclusions The 5% LDSSAF is highly predictive of total claim volumes and is useful for modeling practice trends. There is wide variation in MMS provider annual case volume. These data reflect only Medicare Part B enrollees in 2009; 5% LDDSAF extrapolations are predictions based on sampling.
引用
收藏
页码:1427 / 1434
页数:8
相关论文
共 20 条
[11]  
Kostecki M, 2009, DERMATOLOGY PRACTICE
[12]   Basal cell carcinoma treated with Mohs surgery in Australia - I. Experience over 10 years [J].
Leibovitch, I ;
Huilgol, SC ;
Selva, D ;
Richards, S ;
Paver, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (03) :445-451
[13]   Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years [J].
Leibovitch, I ;
Huilgol, SC ;
Selva, D ;
Hill, D ;
Richards, S ;
Paver, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (02) :253-260
[14]   The management of melanoma and nonmelanoma skin cancer: A review for the primary care physician [J].
Martinez, JC ;
Otley, CC .
MAYO CLINIC PROCEEDINGS, 2001, 76 (12) :1253-1265
[15]   The Economic Impact of Non-Melanoma Skin Cancer: A Review [J].
Mudigonda, Tejaswi ;
Pearce, Daniel J. ;
Yentzer, Brad A. ;
Williford, Phillip ;
Feldman, Steven R. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (08) :888-896
[16]   Errors in the Interpretation of Mohs Histopathology Sections Over a 1-Year Fellowship [J].
Murphy, Michael E. ;
Brodland, David G. ;
Zitelli, John A. .
DERMATOLOGIC SURGERY, 2008, 34 (12) :1637-1641
[17]   Nonmelanoma skin cancer. [J].
Nguyen T.H. ;
Ho D.Q. .
Current Treatment Options in Oncology, 2002, 3 (3) :193-203
[18]   Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006 [J].
Rogers, Howard W. ;
Weinstock, Martin A. ;
Harris, Ashlynne R. ;
Hinckley, Michael R. ;
Feldman, Steven R. ;
Fleischer, Alan B. ;
Coldiron, Brett M. .
ARCHIVES OF DERMATOLOGY, 2010, 146 (03) :283-287
[19]   A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: Effect of the loss of the Mohs multiple surgery reduction exemption [J].
Rogers, Howard W. ;
Coldiron, Brett M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (01) :96-103
[20]  
Tierney EP, 2009, J DRUGS DERMATOL, V8, P914